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ABSTRACT
Clinical human cytomegalovirus (HCMV) strains invariably mutate when propagated in vitro. Mutations in gene RL13 are se-
lected in all cell types, whereas in fibroblasts mutants in the UL128 locus (UL128L; genes UL128, UL130, and UL131A) are also
selected. In addition, sporadic mutations are selected elsewhere in the genome in all cell types. We sought to investigate condi-
tions under which HCMV can be propagated without incurring genetic defects. Bacterial artificial chromosomes (BACs) provide
a stable, genetically defined source of viral genome. Viruses were generated from BACs containing the genomes of strains TR,
TB40, FIX, andMerlin, as well as fromMerlin-BAC recombinants containing variant nucleotides in UL128L from TB40-BAC4 or
FIX-BAC. Propagation of viruses derived from TR-BAC, TB40-BAC4, and FIX-BAC in either fibroblast or epithelial cells was
associated with the generation of defects around the prokaryotic vector, which is retained in the unique short (US) region of vi-
ruses. This was not observed for Merlin-BAC, fromwhich the vector is excised in derived viruses; however, propagation in epi-
thelial cells was consistently associated with mutations in the unique long b= (UL/b=) region, all impacting on gene UL141. Vi-
ruses derived fromMerlin-BAC in fibroblasts hadmutations in UL128L, but mutations occurred less frequently with
recombinants containing UL128L nucleotides from TB40-BAC4 or FIX-BAC. Viruses derived from aMerlin-BAC derivative in
which RL13 and UL128L were either mutated or repressed were remarkably stable in fibroblasts. Thus, HCMV containing a wild-
type gene complement can be generated in vitro by deriving virus from a self-excising BAC in fibroblasts and repressing RL13
and UL128L.
IMPORTANCE
Researchers should aim to study viruses that accurately represent the causative agents of disease. This is problematic for HCMV
because clinical strains mutate rapidly when propagated in vitro, becoming less cell associated, altered in tropism, more suscep-
tible to natural killer cells, and less pathogenic. Following isolation from clinical material, HCMV genomes can be stabilized by
cloning into bacterial artificial chromosomes (BACs), and then virus is regenerated by DNA transfection. However, mutations
can occur not only during isolation prior to BAC cloning but also when virus is regenerated. We have identified conditions un-
der which BAC-derived viruses containing an intact, wild-type genome can be propagated in vitrowith minimal risk of mutants
being selected, enabling studies of viruses expressing the gene complement of a clinical strain. However, even under these opti-
mized conditions, sporadic mutations can occur, highlighting the advisability of sequencing the HCMV stocks used in experi-
ments.
Human cytomegalovirus (HCMV) is associated with morbid-ity and mortality in immunocompromised individuals and is
the leading infectious cause of birth defects worldwide (1). As a
result, the development of a vaccine capable of eliciting protection
against congenital infection is recognized as a high priority (2).
Antiviral therapy can be highly effective in controlling HCMV
disease but is often confounded by toxicity and the rapid selection
of resistance. Therefore, more effective therapeutic options to
combat HCMV are needed urgently.
In developing novel therapies against a pathogen, researchers
should ideally study strains that accurately represent the causative
agent of disease. Unfortunately, HCMV strains propagated in cell
culture reproducibly lose many of the properties characteristic of
clinical virus. Serial passage of HCMV has been correlated with
reduced virulence (3–6), altered tropism (7–10), decreased natu-
ral killer (NK) cell resistance (11), and loss of cell-associated
growth (7, 10). These alterations are associated with genetic
changes in the virus (7, 12–14). Indeed, a systematic study of
HCMV clinical strains passaged in vitro showed that mutations
were selected reproducibly in a subset of HCMV genes, most com-
monly causing protein truncation by nucleotide substitutions (re-
sulting in in-frame stop codons) or small insertions or deletions
(resulting in frameshifts) (12). Thus, regardless of whether
HCMV clinical strains are passaged on fibroblast, epithelial, or
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endothelial cells, mutations tend to occur in gene RL13, which
encodes a virion envelope glycoprotein affecting efficient cell-to-
cell spread and the release of virus from cells (12, 15). When
HCMV is propagated in fibroblasts, mutations are also selected in
the UL128 locus (UL128L) (16), which encodes three proteins
(pUL128, pUL130, and pUL131A). These proteins associate with
glycoproteins H and L to form a pentameric complex that is re-
quired for efficient infection of epithelial, endothelial, and my-
eloid cells (17–22), but that selectively impedes infection in fibro-
blasts (12, 15, 20, 23, 24). Irrespective of cell type, additional
mutations are often observed in the unique long b= (UL/b=) region
of the genome, which contains 20 genes, including the CXCL
chemokine homologues UL146 and UL147 (25, 26), the NK cell
evasion functions UL135, UL141, and UL142 (27–32), a tumor
necrosis factor receptor homologue (UL144) (33, 34), and a clus-
ter of genes implicated in controlling viral reactivation from la-
tency as well as efficient infection of endothelial cells (UL138,
UL136, UL135, and UL133) (35–40). Sporadic mutations occur
elsewhere and gradually accumulate in strains subjected to pro-
longed passage (14, 41).
To preserve HCMV genomes they can be cloned into a bacte-
rial artificial chromosome (BAC) (42, 43), and infectious virus can
then be recovered by DNA transfection of permissive cells. In the
strain Merlin-BAC, which was generated from a virus that had
undergone only six passages in fibroblasts since isolation, the pro-
karyotic vector was inserted into the noncoding region between
genes US28 and US29 (15). By virtue of the presence of flanking
loxP sites and an internal cre gene, the vector is self-excising so that
virus generated from the BAC differs from the original virus in this
region only by a residual insertion of 40 bp. Mutations in RL13
and UL128 that were acquired in vitro prior to BAC cloning were
repaired so that the final clone (Merlin-BAC) contains the wild-
type (wt) HCMV gene complement. Comparison of the sequences
of Merlin-BAC and Merlin in the original clinical sample showed
that their HCMV components are virtually identical (44). How-
ever, when virus derived from the Merlin-BAC was passaged in
fibroblasts, novel mutations in RL13 and UL128L were selected, in
a similar manner to selection in clinical HCMV strains (15).
Other frequently used BAC-cloned genomes include those
captured from HCMV strains TR (TR-BAC) (45, 46), TB40/E
(TB40-BAC4) (7, 47), and VR1814 (FIX-BAC) (9, 48). However,
the most commonly used versions of these BAC-cloned strains are
incapable of generating a virus containing the wild-type HCMV
gene complement because the region containing genes US2, US3,
and US6 has been replaced in each by a nonexcisable vector, and
each has also suffered mutations during in vitro passage of the
parental virus (23, 44, 49, 50). However, unlike clinical strains that
have been passaged on fibroblasts, the protein-coding regions of
UL128L in these clones appear to be intact. Furthermore, there
have been no reports of mutations in UL128L being selected when
viruses from these BAC-cloned strains are generated in fibro-
blasts. Previously, we investigated the properties of TR-BAC,
TB40-BAC4, and FIX-BAC UL128L by transferring sequences
from each into Merlin-BAC (23). We concluded that the UL128L
genome region of TR-BAC carried no in vitro-acquired muta-
tions; however, single nucleotides were identified within TB40-
BAC4 UL128 (a G to T substitution [GT] in an intron, affecting
splicing) and FIX-BAC UL130 (AG, causing an amino acid sub-
stitution) that were responsible for (i) reduced amounts of penta-
meric complex being present in the virion, (ii) increased cell-free
titers in epithelial and fibroblast cells, and (iii) increased rates of
cell-to-cell spread in fibroblasts but reduced rates in epithelial
cells.
In the present study, we sought to investigate parameters
that would support the propagation of clonal HCMV stocks
that retained genomic integrity. HCMV BAC constructs con-
taining strains Merlin, TR, FIX, and TB40/E provided a defined
clonal source of each virus. We also characterized viruses in
which Merlin-BAC UL128L had been replaced in its entirety by
the corresponding region of TB40-BAC4 or FIX-BAC and
those in which it had been modified by adding only the single
nucleotide differences mentioned above (23). To identify con-
ditions under which HCMV might be propagated without muta-
tions being selected, viruses were derived from BACs and then
passaged in epithelial or fibroblast cells, and the genome popula-
tions were deep sequenced. The frequency with which mutations
(including sizeable deletions) were found across all strains dem-
onstrates the merits of performing HCMV genome sequencing as
a routine quality control step during the production of virus
stocks. Crucially, we showed that it is possible to produce HCMV
stocks containing a stable, complete complement of wild-type
genes by recovering virus in fibroblasts from a self-excising BAC in
which expression of RL13 and UL128L is reversibly repressed.
MATERIALS AND METHODS
Cells and viruses. The cell lines used included primary human fetal fore-
skin fibroblast (HFFF) cells, which were kindly supplied by Graham Far-
rar (CAMR, Salisbury, United Kingdom), and human telomerase reverse
transcriptase (hTERT)-immortalized retinal pigmented epithelial cells
(RPE-1) (ATCC CRL-4000). A cell line (HFFF-Tet) constitutively ex-
pressing the tetracycline (Tet) repressor was derived from hTERT-im-
mortalized HFFFs (HFFF-hTERT) (51) transduced with the Tet repressor
gene (tetR) (15). Cell lines were propagated at 37°C in 5% (vol/vol) CO2 in
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10%
(vol/vol) fetal bovine serum, 100 U ml1 penicillin, and 100 g ml1
streptomycin.
Several of the BAC-cloned HCMV strains and derived variants used in
this study have been described previously (Table 1). Merlin-BAC contains
the full complement of wild-type genes, and the variant BACs used were
identical in sequence to it except in RL13 and UL128L. Thus, each variant
contained the same frameshift mutation in RL13 that had been selected
during propagation of the parental virus in vitro, and each also differed in
UL128L. In addition, each variant was engineered to express enhanced
green fluorescent protein (eGFP) from an internal ribosome entry site
(IRES) inserted immediately downstream of gene UL122 (15). TR-BAC,
TB40-BAC4, and FIX-BAC were kindly provided Jay Nelson (Oregon
Health and Science University, Portland, OR, USA), Christian Sinzger
(University of Tubingen, Germany), and Gabrielle Hahn (Universität-
klinikum Carl Gustav Carus, Dresden, Germany), respectively. An IRES:
eGFP cassette was also inserted after UL122 in these clones.
In silico analysis of HCMVDNA sequences. Sequence comparisons,
the design of recombineering experiments, primer and oligonucleotide
design, and sequence data analysis were performed by using CLC Main
Workbench, version 6, software (CLC Bio). The attributes of primers and
oligonucleotides were verified by using Oligo Explorer, version 1.4 Beta
(GeneLink), and Oligo Analyzer (GeneLink) software. Primers and oligo-
nucleotides were purchased from Sigma-Aldrich as reverse-phase, car-
tridge-purified, lyophilized DNA.
Recombineering of HCMV genomes. All recombineering was per-
formed as described previously (15, 23, 52, 53). Briefly, recombineering
was achieved by successive transformations of Escherichia coli SW102 cells
containing the BACs. A selectable Ampr sacB lacZ cassette was inserted
into the region to be modified, followed by screening by positive selection
Murrell et al.
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on medium supplemented with ampicillin (50 g ml1). The selectable
cassette was then replaced by the required DNA sequence, followed by
negative selection on medium supplemented with sucrose (5%, wt/vol) to
select against sacB expression and with 5-bromo-4-chloro-3-indolyl--D-
galactopyranoside and isopropyl -D-1-thiogalactopyranoside to iden-
tify colonies lacking lacZ expression.
Primers used to insert Tet operators upstream of RL13 and UL131A
have been described previously (15). Primers to insert nucleotides from
TB40-BAC4 and FIX-BAC into Merlin-BAC have also been described
previously (23). Using primers as previously described (28), we also con-
structed a virus lacking UL141 (Merlin UL141) in the background of
Merlin-tetUL128wt, which contains binding sequences for the Tet opera-
tor inserted upstream of UL131A in the Merlin-BAC expressing wild-type
UL128.
Preparation of BACDNA stocks. BAC stocks were prepared by using
a Nucleobond BAC 100 plasmid purification kit (Macherey-Nagel), ac-
cording to the manufacturer’s instructions, for the purification of low-
copy-number plasmids. The concentration of purified plasmid DNA
preparations was determined by using an ND1000 spectrophotometer
(NanoDrop).
Reconstitution of virus from BACs by transfection. Viruses were re-
constituted from BACs by transfection of 0.5 106 epithelial cells, 2 106
HFFF cells, or 2  106 HFFF-Tet cells. HFFF and HFFF-Tet cells were
transfected by electroporation, using program T16 of the Nucleofector II
(Amaxa) and a basic Nucleofector kit (Lonza), according the manufactur-
er’s instructions. On occasions when transfected HFFF or HFFF-Tet cul-
tures were 70% confluent after overnight recovery, additional non-
transfected cells were added. RPE-1 cells were transfected by chemical
transfection using an Effectene kit (Qiagen), according to the manufac-
turer’s instructions for transfection of adherent cells. The efficiencies of
transfection of fibroblast and epithelial cells differed only marginally, with
20 to 35 plaques formed per electroporation in HFFF or HFFF-Tet cells
and 50 to 60 plaques formed in RPE-1 cells.
Preparation of viral stocks for sequencing fromRPE-1 cells. Follow-
ing transfection, infected cultures were maintained until plaques were
visible. In RPE-1 cell cultures, infected cells were then trypsinized weekly
and reseeded into fresh flasks. As well as modeling the way in which
viruses are commonly grown for experimental use, this also reduced the
time until 100% cytopathic effect (CPE) was observed (minimizing the
chance of mutants being selected) and reduced the selective pressure for
selection of mutants that favor cell-free spread. This procedure was con-
tinued until 100% CPE was observed, at which point the cells were
trypsinized and cocultured with 6 106 uninfected RPE-1 cells. Cultures
were again trypsinized weekly until 100% CPE was observed, and then the
infected cells were cocultured with 3 107 uninfected RPE-1 cells. When
100% CPE was observed, virus was harvested from the supernatant every
2 days and stored at 80°C. When complete lysis had occurred, the su-
pernatants were thawed, pooled, and cleared by centrifugation at 1,200
g for 3 min, and then virus was pelleted at 30,000 g for 2 h before being
resuspended in DMEM–10% fetal calf serum (FCS).
Preparation of viral stocks for sequencing fromHFFF cells. In HFFF
cells, a protocol of weekly trypsinization, as used in RPE-1 cells, was em-
ployed for viruses that spread predominantly by the cell-to-cell route. As
indicated above, this was done in order to model the way in which viruses
are commonly grown for experimental use and to minimize the chance of
mutants being selected by reducing both the time until 100% CPE was
observed and the selective pressure for mutants that favored cell-free
spread. For viruses that already spread efficiently by the cell-free route,
cultures were maintained without splitting. When 100% CPE was ob-
served, virus was harvested from the supernatant, concentrated as de-
scribed above, and titrated by immunostaining the HCMV IE1 protein
(see below). Uninfected HFFF cells were then infected at a multiplicity of
infection (MOI) of 0.05, and virus was again allowed to spread through
the monolayer until 100% CPE was observed, at which point virus was
harvested and titrated. This procedure was repeated five times.
Preparation of viral stocks from HFFF-Tet cells for sequencing. In
HFFF-Tet cells, all viruses spread by the cell-free route. Cultures were
maintained until 100% CPE was observed, and then cell-free virus was
used to infect 3  107 uninfected cells. When 100% CPE was observed,
virus was harvested every 2 days before being pooled and concentrated as
described above.
Quantification of infectivity. Infectivity was quantified by titration in
HFFF cells, which are the only cells that supported productive infection by
all the HCMV strains and variants used. Viruses were quantified by plaque
titration assay in which cells were inoculated with a range of 10-fold dilu-
tions prepared from each viral stock and then incubated under an overlay
composed of a mixture (1:1) of 2DMEM and Avicel, which limited viral
dissemination to the cell-to-cell route (54). Two weeks later, the overlay
TABLE 1 BAC-cloned HCMV strains and derivatives used
HCMV strain Name
GenBank
accession no. Reference UL128L origin and nucleotide featuresb
Designation of
derived virus
BAC-cloned strainsa
Merlin Merlin-BAC GU179001.1 15 Wild-type Merlin-UL128Lwt
GA in UL128 at nt 176260 (Rstop) Merlin-UL128Lmut
TR TR-BAC AC146906.1 45 Intact TR
TB40/E TB40-BAC4 EF999921.1 47 Intact TB40
VR1814 FIX-BAC AC146907.1 48 Intact FIX
Clinical strain (nonpassaged)
3301 GQ466044.1 41 Wild type 3301
Merlin derivatives
Containing UL128L of other strains 23 3301 Merlin-UL128L3301
TR Merlin-UL128LTR
TB40-BAC4 Merlin-UL128LTB40
FIX Merlin-UL128LFIX
Containing single nucleotides from
UL128L of other strains
23 TB40-BAC4 GT in UL128 at nt 176612 (intron) Merlin-UL128GT
FIX-BAC AG in UL130 at nt 177364 (SP) Merlin-UL130AG
a GenBank accession numbers for the BAC-cloned parental strains are as follows: Merlin, NC_006273.2 (74); TR, KF021605.1 (46); VR1814, GU179289.1 (9). An accession number
for strain TB40/E (7) is not available.
b Nucleotide positions are relative to the sequence of BAC-cloned HCMV strain Merlin (GenBank accession number GU179001). nt, nucleotide.
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was removed, the plate was washed with phosphate-buffered saline (PBS),
and plaques were counted. Alternatively, titration was performed by im-
munostaining the HCMV IE1 protein.
For immunostaining, cells grown in clear-bottomed, 96-well plates
were infected, and, after 12 to 24 h of incubation, they were fixed in 4%
(wt/vol) paraformaldehyde and then permeabilized with PBS containing
0.1% (vol/vol) Triton X-100. All treatments of cells were performed for 10
min at room temperature and followed by three washes in excess PBS. The
primary antibody was a monoclonal mouse anti-IE1 antibody (MA1-
7596; ThermoScientific) diluted (1:1,000) in PBS and incubated for 1 h at
37°C. Samples were washed in excess PBS and then incubated with Alexa
Fluor 594-conjugated goat anti-mouse antibody F(ab=)2 fragment
(A11020; Invitrogen) diluted (1:500) in PBS for 30 min at 37°C. Finally,
the cells were washed in PBS, and fluorescently stained nuclei were
counted.
Viral genomic DNA extraction. In initial experiments with virus de-
rived from RPE-1 cells, there was a concern that the levels of viral DNA in
virions would not be sufficient for sequencing. Therefore, viral genomic
DNA was amplified by infecting HFFF cells at a high MOI and harvesting
DNA at 3 days postinfection, conditions under which there was little
chance of mutations occurring, and only small differences in the relative
ratios of any mutant genomes were anticipated. Viral DNA was harvested
from infected cells by using a DNeasy blood and tissue kit (Qiagen).
For the two viruses (Merlin-UL128Lwt and Merlin expressing UL128L
from unpassaged strain 3301 [Merlin-UL128L3301]) (Table 1) for which
titers were insufficient to perform infections at high MOIs, viral genomic
DNA was extracted directly from 100 l of cell-free virus stock by using a
MinElute virus spin kit (Qiagen) according to the manufacturer’s instruc-
tions. This method proved successful and was thereafter used for sequenc-
ing of all viruses, including all those from HFFF and HFFF-Tet cells.
High-throughput sequencing of HCMV genomes. Sequence read
data sets were generated from viral genomic DNA by using a MiSeq system
(Illumina, San Diego, CA, USA). DNA (1,000 ng) from each sample was
sheared by sonication, and DNA fragments were purified and size selected
by using AMPure XP beads (Beckman-Coulter, High Wycombe, United
Kingdom). The DNA fragments were end repaired, 3= adenylated, ligated
to paired-end multiplexing adapters, and amplified by PCR using stan-
dard methods (Illumina). The data sets were filtered to remove nucleo-
tides with a phred quality of 30 and processed for adapter removal by
using Trim Galore, version 0.2.2 (http://www.bioinformatics.babraham
.ac.uk/projects/trim_galore). The filtered reads were aligned against ref-
erence sequences by using the Burrows-Wheeler Aligner (BWA), version
0.6.2-r126 (55). Indexed bam files were generated from the alignments by
using Samtools, version 0.1.18 (55), and viewed manually throughout
using Tablet, version 1.12.12.05, in order to highlight any differences (56).
Genome coverage ranged from 99.855 to 100%, average depth ranged
from 117.841 to 769.865 reads/nucleotide.
Sanger DNA sequencing. When high-throughput sequencing identi-
fied mutations in viruses passaged in HFFF cells, Sanger sequencing was
used to determine at which passage the mutations became detectable. The
appropriate region of the genome was PCR amplified from viral genomic
DNA isolated from each passage. PCR products were then sequenced by
Sanger sequencing (Eurofins MWG). Primers used for PCR and sequenc-
ing reactions are listed in Table S1 in the supplemental material. Sequence
data were analyzed using the CLC Main Workbench and compared with
those derived by high-throughput sequencing.
RESULTS
Stability ofBAC-derivedHCMVstrains in epithelial cells.A ma-
jor aim of the present study was to identify conditions that would
permit the genetic integrity of low-passage-number HCMV
strains to be retained during the preparation of viral stocks.
UL128L is problematic because it impedes growth in fibroblasts,
whereas it is required for the efficient infection of epithelial, en-
dothelial, and myeloid cells (12, 15, 16). Several different HCMV
BAC constructs (Table 1) were therefore transfected into epithe-
lial (RPE-1) cells, with the aim of keeping UL128L functionally
intact. Viruses derived from TR-BAC, TB40-BAC4, FIX-BAC, and
Merlin-BAC were analyzed, as well as several from variant Merlin
TABLE 2 Mutant populations in viruses generated in epithelial (RPE-1) cells
HCMV strain or
derivative
Location of
mutation (nt)a ORF(s) affected Description of mutation and effect on coding
Mutant population
(% of sequenced
population)
TR 3687–9738 US9–US16 6,052-bp deletion 81
159574–159581 UL84 TTTTTTTTTTTTTTTTT (frameshift) 77
TB40 228878–1973 IRS1–US9 Deletion of 173 bp (end of a= to US2), entire BAC vector, and
1,973 bp (US7, US8, and part of US9)
87
155175 UL84 GA (Qstop) 46
Merlin-UL128Lwt 176129–188023 UL128–UL136 11,895-bp deletion with 1,21- bp insertion (part of UL20
flanked by E. coli sequences)
3
Merlin-UL128L3301 180563–194029 UL147–UL150 	13,750-bp deletion with 10,300-bp insertion (inversion of
left genome end to within RL12)
44
Merlin-UL128LTB40 181910–191511 UL145–UL148C 9,602-bp deletion with 3,733-bp insertion (E. coli) 93
183591–186632 UL142–UL139 3,042-bp deletion 6
Merlin-UL128GT 32652 UL26 GT (RS) 48
110792 UL75 GC (LM) 40
185141 UL141 CT (Wstop) 64
204004 US8 AC (VG) 19
Merlin-UL128LFIX 184459–184914 UL141 456-bp in-frame deletion 100
a Locations are based on the sequences of TR-BAC (GenBank accession number AC146906.1), TB40-BAC4 (GenBank EF999921.1), and Merlin-BAC (GenBank GU179001.1). The
TR-BAC, TB40-BAC4, and FIX-BAC sequences deposited in GenBank commence immediately following the site of vector insertion, and coordinates of mutations in viruses de-
rived from these clones describe sequences either side of the BAC vector. nt, nucleotide.
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BACs (23). These variants included the following: two with wild-
type UL128L, from either Merlin (Merlin-UL128Lwt) or the un-
passaged strain 3301 (Merlin-UL128L3301), which incorporate
high levels of the pentameric complex into virions; one unable to
synthesize the pentameric complex (Merlin-UL128Lmut); two
containing sequences from TB40-BAC4 (either the entire UL128L
[Merlin-UL128LTB40] or a previously identified single nucleotide
variation in UL128 [Merlin-UL128GT]); and two containing se-
quences from FIX-BAC (either the entire UL128L [Merlin-
UL128LFIX] or a single nucleotide variation in UL130 [Merlin-
UL130AG]). For the last four constructs, we have shown that the
levels of the pentameric complex incorporated into virions are
reduced relative to levels in wild-type Merlin (23). Merlin-
UL128Lmut and FIX do not grow in RPE-1 cells (23), but viruses
were generated from all other BAC constructs, expanded until 3
107 cells were infected, harvested, and then sequenced.
Although UL128L remained intact in all but one virus propa-
gated in RPE-1 cells, mutations elsewhere were evident in all
stocks (Table 2). By comparing all viruses, two consistent patterns
of mutation were noted. First, TR-BAC and TB40-BAC4 are de-
signed to retain the vector in progeny virus, and this feature ap-
peared to have an impact on the stability of the viral genome in
that HCMV sequences either within or adjacent to the vector were
deleted in viruses derived from both BACs. The major TR popu-
lation had a deletion from US9 to US16, supplemented by a frame-
shift mutation in UL84 (Fig. 1A and Table 2). The major TB40-
BAC4 population had lost the entire vector sequence together
with flanking HCMV sequences encoding residual portions of
US2 and US7-US9 (Fig. 1B) and also had a premature stop codon
in UL84.
All Merlin variants were produced by using a self-excising vec-
tor system (15), and mutations were not associated with the region
FIG 1 Mutant populations detected in stocks of virus derived from TR-BAC and TB40-BAC4 in RPE-1 cells. (A) TR. The top of the panel shows a schematic of
TR-BAC. Enlarged boxes represent sequences repeated at each genome segment terminus (a sequences in gray; b and c sequences in white); the connecting black
line represents regions of unique sequence, UL and US; the black star indicates the site of the stably incorporated BAC vector insertion. ORFs US9 to US16 in the
parental TR BAC are shown (i), and sequence deleted (green) in the mutated TR genomes, originating from within US9 and spanning ORFs up to and including
part of US16, is indicated (ii). (B) TB40-BAC4. The top of the panel shows a schematic of TB40-BAC4. The a=-US9 region in the parental TB40-BAC4, including
the a= sequence (red) fused to the remainder of ORF US2, the BAC vector (blue), US7, US8, and US9, is shown (i). Sequence deleted (green) in the mutated
TB40-BAC4 genome, originating from the a= terminus up to and including part of US9, is indicated (ii).
Genetic Stability of HCMV In Vitro
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from which the vector had been excised. However, other muta-
tions occurred. UL128L was stable within the Merlin viruses, ex-
cept for Merlin-UL128Lwt, in which a small minority (3%) of
the population contained a deletion of UL128 to UL136, replaced
by a sequence derived from US20 flanked by E. coli sequences (Fig.
2). Indeed, a range of deletions and mutations in the UL/b= region
(UL148 to UL150) affected nearly all Merlin-based viruses (Table
2; Fig. 2). Thus, Merlin-UL128L3301 suffered a deletion of UL147
FIG 2 Mutant populations detected in stocks of Merlin viruses produced in RPE-1 epithelial cells. At the very top of the figure a schematic of the Merlin-BAC
genome is shown. Enlarged boxes represent sequences repeated at each genome segment terminus (a sequences in gray; b and c sequences in white); connecting
black lines represent unique sequence UL and US genome regions; the star indicates the site of self-excising BAC vector insertion in the US28-US29 intergenic
region. (A) Organization of ORFs UL128 to UL150 in the parental Merlin-BAC. (B) In Merlin-UL128Lwt, mutant genomes underwent deletion (green) of
sequence spanning UL128 to UL138 and part of UL136, with concomitant insertion of E. coli DNA (dark gray) and duplication of part of US20. (C) In
Merlin-UL128L3301, mutant genomes underwent deletion of sequence from within UL147, up to and including UL150, with concomitant insertion of duplicated
sequence (UL-start to RL12). (D) In Merlin-UL128L
TB40, two mutant genomes were detected: (i) a major population showing a loss of sequence from within of
UL145 up to UL148C, with concomitant insertion of E. coliDNA; (ii) a minor population showing a loss of sequence from within UL142 up to and including part
of UL139. (E) In Merlin-UL128GT, mutant genomes encoded a nonsynonymous single nucleotide polymorphism (purple) in UL141. (F) In Merlin-UL128LFIX,
mutant genomes underwent an in-frame deletion (green) in UL141.
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to UL150 that was compensated by duplication of RL1 to RL12
(Fig. 2C), Merlin-UL128LTB40 consisted primarily of a deletion of
UL145 to UL148C (replaced byE. coliDNA) and a low-abundance
deletion of UL142 to UL139 (Fig. 2D), Merlin-UL128LFIX exhib-
ited a mutation in UL141 (Fig. 2E) in the majority of genomes, and
Merlin-UL128GT had a UL141 deletion (Fig. 2F). Thus, muta-
tions affecting UL141 were repeatedly identified in Merlin-based
viruses during passage in RPE-1 cells. To determine whether this
was directly due to UL141, UL141 was deleted from Merlin-
tetUL128wt (MerlinUL141), and both cell-free titers and plaque
sizes were measured following infection of epithelial cells (Fig. 3A)
or HFFF (Fig. 3B). Both titers and plaque sizes were increased
when virus lacking UL141 was grown in RPE-1 cells but not in
HFFFs. Thus, loss of UL141 provides a selective advantage in
RPE-1 cells.
Mutations outside the UL/b= region were identified in some
instances and included amino acid substitutions affecting UL26,
UL75, and US8 (Table 2). Merlin-UL130AG was unusual in
maintaining its genomic integrity in the short-term culture in-
volved in this experiment. However, this virus was recovered only
once in RPE-1 cells. Given that UL141 restricts virus growth in
RPE-1 cells (Fig. 3) and that all other Merlin viruses experienced
mutations in UL/b=, it seems likely that mutations in the UL/b=
genome region of Merlin-UL130AG would also be selected upon
further culture.
In summary, although it is possible to conserve the sequence
and function of UL128L by culturing HCMV in epithelial cells,
almost all viruses assessed (7/8) acquired mutations elsewhere in
the genome, in particular, around the site of the vector (if it was
retained following generation of virus) or in UL/b=, centered on
UL141. This general instability undermines confidence in the use
of this cell type for extended HCMV propagation.
Stability of BAC-derived HCMV strains in fibroblasts. Since
passage of HCMV in epithelial cells was consistently associated
with mutation, all BACs (Table 1) were transfected into fibro-
blasts, and virus was allowed to spread through the monolayers.
Cell-free virus was then collected and used to infect a fresh mono-
layer at a low MOI, and virus was allowed to spread. This was
repeated five times before viral DNA was sequenced. In this man-
ner, samples archived at each passage could be used to track
when mutations emerged by retrospective PCR amplification
and sequencing. In each case in which a mutation was observed
during generation of virus, the mutation was not detected in
the parental BAC.
The mutation in the BAC used to generate Merlin-UL128Lmut
was selected naturally when Merlin was first isolated from the
clinical sample. In two independent transfection experiments, the
sequence of Merlin-UL128Lmut at passage 5 exactly matched that
of the parental BAC (minus the vector). However, when strain
Merlin contained a wild-type UL128L, either from Merlin itself
FIG 3 Comparison of growth of Merlin-tetUL128wt (Merlin) with that of the same virus, but with UL141 deleted (MerlinUL141). (A) RPE-1 cells were transfected
with Merlin or with Merlin UL141. At the indicated times, supernatant was titrated on HFFF cells. Alternatively, at 3 weeks posttransfection (PT), plaque sizes were
measured. (B) HFFF cells were infected with Merlin or Merlin UL141. At the indicated times, supernatant was titrated on HFFF cells. Alternatively, at 2 weeks
posttransfection, plaque sizes were measured. Error bars show standard errors of the means; data were analyzed by two-way analysis of variance (cell-free titers) or t test
(plaques sizes). PI, postinfection.
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(Merlin-UL128Lwt) or the unpassaged strain 3301 (Merlin-
UL1283301), the majority of genomes suffered mutations involv-
ing UL128L. The major population in Merlin-UL128wt contained
a deletion extending from UL128 to UL139 (Table 3 and Fig. 4B,
part i), and a second population contained a frameshift in UL131A
(Fig. 4B, part ii). In Merlin-UL128L3301, a frameshift was observed
in UL128 (Fig. 4C), as well as a substitution in the region between
UL54 and UL55. Retrospective investigation detected each of
these genetic changes at passage 1.
Following serial passage in fibroblasts, UL128L sequences in
strains TR, TB40, and FIX all matched exactly the corresponding
sequences in the parental BACs. However, all three strains exhib-
ited substantial deletions elsewhere in the genome, which were
reminiscent of the rearrangements observed during propagation
of viruses derived from the same BACs in epithelial cells (Table 3).
In TR, two distinct mutations were detected, both comprising the
deletion of a sequence extending from the a= region to a site within
the vector (Fig. 5A). In TB40-BAC4, virus lacked sequence ex-
tending from within a=, across the entire vector, into US7 (Fig.
5B). In FIX, a deletion was observed extending from immediately
outside the terminal a= sequence, across the entire vector, into US2
(Fig. 5C). Thus, in all three strains, mutations were linked to the
vector, and these were selected rapidly, being detected at passage 1.
Wild-type UL128L represses the growth of Merlin in fibro-
blasts, and mutations are selected rapidly (12, 15, 23, 24) (see
above). When the entire UL128L region or the previously identi-
fied single nucleotide substitutions in UL128L of TB40-BAC4 or
FIX-BAC were inserted into the Merlin genome, repression of
virus spread and release in fibroblasts were less pronounced
(23). In accord with this finding, only one of the four Merlin-
based viruses containing UL128L sequences from these BACs
(Merlin-UL128LTB40, Merlin-UL128LFIX, Merlin-UL128GT,
and Merlin-UL130AG) acquired mutations in UL128L, with
Merlin-UL128LTB40 experiencing the loss of UL130 to UL148 by
passage 1 (Fig. 6). Mutations were observed elsewhere in the ge-
nomes of three of these viruses, but in two of these they were
associated with the eGFP reporter gene: a TA substitution in
Merlin-UL128LTB40 and a deletion near the 3= end of the gene in
Merlin-UL130AG at passage 2. Only one of these viruses con-
tained mutations in genes outside UL128L and the reporter gene,
with Merlin-UL128GT acquiring amino acid substitutions in
UL47 and UL55 by passage 4.
Thus, viruses derived from TR-BAC, TB40-BAC4, and FIX-
BAC lack a specific mechanism to excise the vector in eukaryotic
cells and consistently developed mutations within or adjacent to
the vector in fibroblast cells. Merlin-BAC was designed to self-
excise the vector in mammalian cells (57, 58), and this eliminated
the problem. As a result, viruses derived from Merlin-BAC were
stable during multiple passages as long as expression of UL128L
was impaired by suitable mutations introduced into the BAC.
Variants that contained reduced levels of the pentameric complex
in the virion (due to the presence of nucleotides derived from
TB40-BAC4 or FIX-BAC) acquired mutations in UL128L muta-
tions only rarely. However, mutations were occasionally detected
elsewhere in the genome.
Repression of RL13 and UL128L enables stable passage of
viruses containing the complete, wild-type HCMV gene com-
plement in fibroblasts. In situations in which expression of the
pentameric complex was ablated or substantially reduced by mu-
tation of UL128L, viruses derived from Merlin-BAC only rarely
TABLE 3 Mutant populations viruses generated by 5 passages in fibroblast (HFFF) cells
Virus
Mutation
location (nt)a
ORF(s)
affected Mutation and/or coding effect
Mutant population (% of
sequenced population)
Merlin-UL128Lmut No de novo mutations detected
Merlin-UL128Lwt 176320–187358 UL128–UL139 11,039-bp deletion 97
178063–178066 UL131A 4-bp deletion; frameshift 3
Merlin-UL128L3301 228878–446 UL128 exon 1 G insertion; frameshift 64
81884 UL54/UL55 IG GA substitution
TR 194202-BAC a=-US3 6,087-bp deletion: 3,899 bp from a= to the BAC vector, plus
2,188 bp of the BAC
92
4,306-bp deletion: 3,899 bp from a= to the BAC vector, plus 407
bp of the BAC
92
TB40-BAC4 228878–446 US7 Deletion of 173 bp from a= to the BAC vector, entire BAC vector,
and 446 bp into US7
6
FIX 228002–60 7,650-bp deletion; sequence from a= to BAC vector plus 7 bp 100
Merlin-UL128LTB40 177130–179950 UL130–UL148 2,807-bp deletion 54
NA eGFP TA substitution 61
Merlin-UL128GT 61647 UL47 GC (DH) substitution 29
83915 UL55 TA (DV) substitution 11
Merlin-UL128LFIX No de novo mutations detected
Merlin-UL130AG NA eGFP 720-bp deletion 99
a Locations are based on the sequences of TR-BAC (GenBank accession number AC146906.1), TB40-BAC4 (GenBank EF999921.1), and Merlin-BAC (GenBank GU179001.1). The
TR-BAC, TB40-BAC4, and FIX-BAC sequences deposited in GenBank commence immediately following the site of vector insertion, and coordinates of mutations in viruses de-
rived from these clones describe sequences either side of the BAC vector. NA, not available; nt, nucleotide.
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acquired de novo mutations during passage in fibroblasts (above).
The Merlin-UL128Lmut BAC (lacking RL13 and UL128) has thus
far been used to generate 44 different HCMV recombinants or
mutants, and their genomes have been sequenced (30, 59). A total
of 40 viruses had genome sequences that were identical to the
sequence of the parental BAC (minus the vector), and only four
were mutated (Table 4). These mutations include deletion of viral
genes, incorrect excision of the vector, and incorporation of an E.
coli insertion element. Thus, although these viruses were generally
stable, apparently random mutations occurred in about 10% of
viruses following passage in vitro.
Although viruses lacking RL13 and UL128L proved to be gen-
erally stable and although they have been used in many studies
because of this property, the inability of these viruses to infect cell
types relevant to intra- and interhost dissemination (e.g., epithe-
lial cell, endothelial cell, myeloid cell types), as well as the altered
growth phenotypes they display compared to the growth pheno-
type of clinical virus (i.e., a predisposition for cell-free virus
spread, as opposed to cell-to-cell spread), means that it is desirable
to be able to generate and passage viruses retaining wild-type ver-
sions of RL13 and UL128L (44, 60–72). Previously, we exploited a
Tet-regulated system to repress expression of RL13 and UL128L
during generation of virus from a BAC (15). In the present study,
we hypothesized that Tet repression of RL13 and UL128L
would enable virus encoding the complete, wild-type gene
complement to be propagated stably and efficiently in vitro. To
test this, binding sequences for the Tet operator were insert-
ed upstream of UL131A in the Merlin-UL128Lwt (Merlin-
tetUL128Lwt), Merlin-UL128GT (Merlin-tetUL128GT), and
Merlin-UL130AG (Merlin-tetUL130AG) BACs. Tet operators
were also inserted upstream of a repaired RL13 gene in a virus
either lacking UL128 (Merlin-tetRL13wt) or containing UL128
(Merlin-tetRL13wt/tetUL128Lwt). Viral stocks were generated
from all BACs in HFFF-Tet cells. The genome sequences of single
viruses (Merlin-tetUL128GT and Merlin-tetUL130AG) or du-
plicate viruses (Merlin-tetUL128wt, Merlin-tetRL13wt, and Mer-
lin-tetUL128Lwt/tetRL13wt) independently derived from each
BAC were identical to those of the parental BACs (minus the vec-
tor). Thus, repression of RL13 and UL128L enabled the passage of
virus containing the complete gene complement of HCMV, with
minimal risk of mutations being acquired or selected de novo.
DISCUSSION
The capacity of clinical HCMV strains to accumulate mutations
rapidly and progressively during propagation in vitro has resulted
in research being conducted on viruses that differ from strains
circulating in vivo in terms of their genetic content and in terms of
important phenotypes such as tropism, immunomodulation, cell-
associated dissemination, and virulence (12, 14, 41, 44, 73). The
advent of BAC technology has provided a potential way around
this problem by facilitating access to a stable, characterized, clonal
source of the viral genome. However, there are problems with this
FIG4 Mutant populations detected in viruses derived from Merlin-BAC variants containing wild-type UL128L ORFs from strain Merlin or from the unpassaged
strain 3301 following five sequential passages in HFFFs. A schematic of the BAC-cloned Merlin genome, as previously described (Fig. 2), is shown at the top of
the figure. (A) Layout of ORFs UL128 to UL138 in parental Merlin-BAC constructs. (B) Mutant populations detected in Me-UL128Lwt: (i) a major population
underwent deletion (green) of sequence from within UL128 and ending in the UL138/UL139 intergenic region; (ii) a minor mutant population underwent a
frame-shifting 4-bp deletion (purple) in UL131A. (C) In Merlin-UL128L3301, mutant genomes acquired a frame-shifting insertion of a G residue, as well as a
single nucleotide substitution (CT) (red) at a neighboring residue position, in UL128 exon 1.
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FIG 5 Mutant populations detected in viruses derived from TR-BAC, TB40-BAC4, and FIX-BAC following five sequential passages in HFFFs. (A) Mutant
populations detected in TR virus. A schematic of TR-BAC, as previously described (Fig. 1), is shown at the top of the panel. The junction of the short internal
repeat (IRS) and US regions in the parental TR-BAC is shown, including part of a= and c= sequence repeats (red), ORFs IRS1 and US1, and remaining fragments
of US2 and US6, disrupted by insertion of the BAC vector sequence (blue). Sequences deleted (green) in mutated TR genomes, originating from adjacent to the
a= sequence and up to different positions in the BAC vector, are indicated (ii). (B) Mutant populations detected in TB40-BAC4 virus. A schematic of TB40-BAC4
genome, as previously described (Fig. 1), is shown at the top of the panel. The junction of the short internal repeat and US regions in the parental TB40-BAC,
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approach that need to be addressed. In order to generate a BAC, a
clinical HCMV strain is normally isolated and expanded in vitro as
a prelude to cloning the genome into a BAC vector, and the virus
is likely to mutate during this process. This risk can be monitored
by comparing the sequence of the BAC-cloned genome with that
of the original clinical sample, carrying out repairs as required.
Without this comparison, there is no guarantee that mutations
will be identified since these may be subtle in their effects (e.g.,
they may cause amino acid replacements or affect noncoding
functions) (12, 23, 44, 49, 74). Furthermore, even if the sequences
of the clinical virus and the BAC-cloned genome match exactly,
there is a possibility that mutations will be acquired when virus is
generated from the BAC, as we have demonstrated previously (15)
and in the present study. This risk can be assessed by sequencing
the genome of the virus generated. As a result of exploring this
double jeopardy and identifying potential control points, we have
identified a method for propagating HCMV through multiple se-
rial passages while retaining an intact complement of genes.
TR-BAC, TB40-BAC4, and FIX-BAC are used widely and con-
tain intact protein-coding regions in UL128L. We have demon-
strated that, during passage of the viruses derived from these BACs
in fibroblasts, mutations are less likely to be selected in UL128L
than when virus derived from Merlin-BAC is passaged. In the
cases of TB40-BAC4 and FIX-BAC, this property likely results
from subtle mutations in UL128 and UL130, respectively, which
we have shown previously reduce the level of UL128L proteins in
the virion, thereby reducing the inhibitory impact of UL128L on
viral growth in fibroblasts (23). Genetic differences outside
UL128L may also contribute to the stability of UL128L in these
strains since no mutations were selected in UL128L of TR, FIX, or
TB40 following generation in fibroblasts, and yet when UL128L
sequences from TB40-BAC4 were placed into Merlin-BAC (Mer-
lin-UL128TB40), mutations in UL128L were selected in one of the
two viruses analyzed. Similarly, we previously observed the selec-
tion of mutations in TR UL128L when it was placed into the Mer-
lin genome (23).
Although mutations in UL128L were not selected when virus
was derived from TR-BAC, TB40-BAC4, or FIX-BAC, de novo
mutations were repeatedly selected in the unique short (US) re-
gion (in association with the vector) whether viruses were propa-
gated in epithelial or fibroblast cells. Mutations affecting the genes
in this region were not observed during a previous study when
viruses derived from clinical material (rather than BACs) were
passaged in cell culture (12). Thus, it is possible that the selection
pressure results from an increase in genome size caused by the
presence of the vector, coupled with genome size limitations op-
erating during virion morphogenesis (57, 75). Indeed, the length
of TR-BAC is appreciably larger (241,327 bp) than that of the
original TR virus (235,029 bp when circularized) although
FIX-BAC (235,597 bp) is only marginally larger than the pa-
rental strain VR1814 (234,614 bp when circularized). Alterna-
tively, the selection pressure may be due to an incompatibility
between part of the US region and the vector that impacts nega-
tively on viral replication in vitro. Irrespective of the reasons, re-
engineering these BACs to contain a self-excising BAC cassette, as
has been done for TR (76), is likely to offer a solution to these
problems. In fact, based on the general scarcity of mutations ob-
served elsewhere in the genomes of TR-BAC, FIX-BAC, and
TB40-BAC4 in this study, such a construct may be quite stable in
culture. However, it should be appreciated that without the se-
quence of the original clinical material, it is impossible to know
how much this stability derives from mutations that have already
occurred (prior to BAC cloning) (15, 23, 44, 49, 50).
Interestingly, mutations affecting UL84 were seen in viruses
derived from both TR-BAC and TB40-BAC4 in RPE cells. This
open reading frame (ORF) encodes a multifunctional protein with
activities to both promote and impede virus replication (77). In
both TR and TB40-BAC4, UL84 is nonessential for growth (78,
79). The N-terminal residues of UL84 interact with UL44 and are
required for genome replication (80), while both the N- and C-
terminal regions are involved in transcriptional repression via in-
teractions with ppUL122 (77). The mutations acquired by TR and
TB40-BAC4-derived viruses each resulted in the loss of C-termi-
nal residues of pUL84. Since the mutants made up 	80% of the
sequenced population, loss of domains involved in the IE2-medi-
ated repressive activity of UL84 may result in a growth advantage
in vitro.
No mutations were observed in the region of the Merlin ge-
nome that contains the residual loxP site following vector self-
excision. However, mutations in the UL/b= region were frequently
selected when viruses were generated in RPE-1 cells. Comparable
genetic changes were observed occasionally in our previous study
when clinical HCMV strains were passaged in vitro without the
involvement of BACs (12). However, this was after at least 32
including the a sequence (red) fused to part of US2, the BAC vector sequence (blue), and US7, is shown (i). Sequence deleted (green) in mutated TB40-BAC4
genomes, originating from within the a= sequence, encompassing the BAC vector, and disrupting US7, is indicated (ii). (C) Mutant populations detected in virus
from FIX-BAC. A schematic of the parental FIX-BAC is shown at the top of the panel. ORFs in the US genome region are inverted compared to those in the UL
genome region, and the genome lacks a terminal c sequence in the short terminal repeat genome region. The junction of the short terminal repeat and US regions
in the parental FIX-BAC genome, including US7, the BAC vector sequence (gray), the remaining part of US2 that is fused to the terminal a sequence (red) in the
short terminal repeat region, is shown (i). Sequence deleted (green) in mutated FIX genomes, encompassing the BAC vector sequence and up to within the a
sequence, is indicated (ii).
FIG 6 Mutant populations in stocks of Merlin variants containing UL128L
ORFs from TB40-BAC4 following five passages in HFFFs. Schematic of the
BAC-cloned Merlin genome as described previously (Fig. 2). (A) ORFs UL128
to UL148 in parental Merlin-UL128LTB40. (B) In Merlin-UL128LTB40 at pas-
sage 5 in HFFFs, sequence was deleted from within UL130 and ending in
UL148.
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weeks of propagation, whereas, in the current study, mutations
appear to have been selected much more rapidly. This may reflect
the different ways in which viruses were grown in the two studies.
In the previous study, cultures were small and were split weekly so
that the number of infected cells remained low. In the present
study, cultures were grown until complete infection was observed
and then expanded to include a much greater number of infected
cells before cell-free virus was harvested. It is notable that all of the
mutations in the UL/b= region detected in viruses generated from
Merlin BACs in epithelial cells involved the loss of UL141, with
some viruses showing mutation of this gene alone. This confirms
and extends the observations from our previous study, in which
we reported that the region of UL145 to UL140 was prone to
mutation during passage of clinical HCMV strains in vitro, albeit
that previously loss of this gene region occurred in both fibroblast
and epithelial cells (12). Thus, in addition to being an immune
evasion gene (28, 29, 31), UL141 is inhibitory to the growth of
HCMV in epithelial cell culture, with selection against UL141 pre-
sumably resulting in loss of adjacent genes in UL/b= in this cell
type. Since UL141 downregulates levels of the proteins CD155,
CD112, and TrailR2 from the infected cell surface (28, 29, 31),
fluorescence-activated cell sorting (FACS) analysis could be used
to determine whether mutations involving UL141 have occurred
in any given virus stock. UL141 is also mutated in TB40-BAC4
(47), whereas neither TR-BAC- nor FIX-BAC-derived viruses suf-
fered deletions in the UL/b= region during passage in epithelial
cells. This difference could be due to the acquisition of subtle,
unrecognized mutations in this region, similar to those previously
identified in RL13 and UL128L of TB40-BAC4 and FIX (23), or it
may indicate genuine strain-specific differences. Identifying
strain-specific phenotypes, without the confounding effects of in
vitro mutations, will require the construction of validated BAC-
cloned HCMV genomes from independent HCMV clinical iso-
lates (44).
Another interesting observation was that in one virus (Merlin-
UL128wt), a minority population of mutants in UL128L was se-
lected despite this genome region being required for efficient in-
fection in RPE-1 cells. Presumably, this could only happen if the
genome lacking UL128L was complemented by coinfection with a
wild-type genome. All viruses that suffered large deletions during
passage in RPE-1 cells contained additional sequence in place of
the UL/b= region, either viral or E. coli DNA. Deep sequencing
detected E. coli DNA in DNA preparations for transfection; pre-
sumably this was the source of DNA that subsequently recom-
bined with the virus genome during passage. Nevertheless, al-
though growing viruses in RPE-1 cells generally prevents selection
of mutations in UL128L, the frequent selection of mutations in the
UL/b= region necessitates the exercise of caution in using these cells
for extended passage of HCMV.
Whereas the mutations that occurred in viruses derived from
Merlin BACs in epithelial cells tended to be localized to the UL/b=
region, those in fibroblasts tended to occur in UL128L, with the
likelihood of mutation correlating with the parental UL128L se-
quence. Thus, whereas viruses containing wild-type UL128L suf-
fered from mutations involving UL128L, viruses expressing re-
duced levels of the pentameric complex due to the insertion of
nucleotides from TB40-BAC4 or FIX-BAC UL128L (23) exhibited
such mutations less commonly (1/4 viruses). Moreover, viruses in
which UL128L expression was completely ablated by mutation, or
reduced by Tet repression, did not mutate in UL128L, and addi-
tional mutations elsewhere in the genome were rare (4/54 viruses).
The effects of the rare mutations outside UL128L ranged from
amino acid sequence changes in important immunological targets
(e.g., UL55, encoding glycoprotein B [gB]) to loss of multiple
genes (e.g., US29 to US34A) (Table 4). In some cases, these mu-
tations occurred during passage of BAC-derived virus, although in
two cases the acquisition of a transposon apparently occurred inE.
coli. The use of bacterial strains that have been engineered to re-
move mobile DNA may help solve the problem of transposon
insertion (81), while alternative methods of introducing BAC
DNA into cells, such as invasive bacteria (82) or adenofection
(83), may reduce the chances of mutations being generated during
transfection.
Nevertheless, these apparently random mutations, and the
mutations seen around the vector in viruses generated from TR-
BAC, TB40-BAC4, and FIX-BAC, raise an important issue. Vi-
ruses derived from HCMV BACs are used widely, often to study
the effects of specific genetic changes (e.g., deletion of a gene of
interest). It is generally assumed that the only substantive differ-
ence between the parental BAC and the generated virus will be the
intended modification. Revertants are often produced to control
off-target mutations, involving repair of the modified sequence
within the BAC. This type of control may suffice for identifying
alterations introduced unintentionally during the process of BAC
modification, but it is inadequate for monitoring unanticipated
changes arising after the BAC is transfected into eukaryotic cells. It
is possible to safeguard against this risk by deriving and analyzing
multiple viruses from the same BAC. However, the sequencing of
the viral stocks to be used in experiments offers a more robust,
TABLE 4 Mutations in 4/44 Merlin-UL128Lmut-derived viruses following passage in fibroblasts
Location of
mutation (nt)a
ORF(s)
affected Mutation and/or coding effect
Mutant population (% of
sequenced population)
29048 UL23–UL24,
intergenic
CT 55
29531–31054 UL23–UL24 1,504-bp deletion 64
BAC-240244 US29–US34A 2,215 nt of the left-hand end of the BAC vector remains; there is a 72-nt duplication of a BAC
sequence, then a deletion encompassing the remainder of the BAC cassette, and a deletion
of 5,076 nt of the HCMV coding sequence to the right of the BAC
100
18049–18050 UL10 1,338-bp insertion (1,329 bp of E. coli sequence plus 9 bp of duplicated viral sequence) 76
206155–206156 US11 1,190-bp insertion of E. coli IS150, plus a 3-nt duplication of viral sequence 100
206155–206156 US11 1,190-bp insertion of E. coli IS150 (opposite orientation to above) 100
a Relative to Merlin-BAC (GenBank accession number GU179001.1). nt, nucleotide.
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informative, and economical method for validating genomic in-
tegrity.
In this study, whole-genome sequencing of BAC-derived viral
genomes enabled us to identify methods to passage HCMV ge-
nomes stably in vitro. Infectious HCMV BACs provide an excel-
lent source of fully characterized genomic DNA and clonal virus.
We have learned that propagation of BAC-derived virus in epithe-
lial cells should be performed with caution since it can lead to the
rapid selection of mutations involving UL141. Where there is a
need to propagate a virus containing the complete, wild-type ge-
nome of an HCMV strain, the strategy that results in the least
chance of unwanted mutations being selected is to derive virus
from a BAC containing a self-excising vector, to passage the virus
in fibroblasts, and to repress the UL128L and RL13 functions.
Repression can be relieved subsequently by infecting HFFF cells
that do not express the Tet repressor or by adding doxycycline,
thus enabling experiments to be performed using virus expressing
the complete gene complement of wild-type HCMV. Clinical
strains consistently acquire mutations in UL128L during passage
in fibroblasts (12), and BAC-cloned strains (e.g., TB40-BAC4 and
FIX) that do not acquire ablative mutations in UL128L during
culture tend to have preexisting mutations that result in smaller
amounts of pUL128L being incorporated into the virion (23).
Thus, it seems likely that repression of UL128L (and RL13) will be
required for the stable passage of any virus where the genome
sequence matches that of a clinical strain.
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